MRG-003 is under clinical development by Shanghai Miracogen and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase II drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRG-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRG-003 overview
MRG-003 is under development for the treatment of unresectable locally advanced or metastatic biliary tract cancer, metastatic colorectal cancer, adenocarcinoma of the gastroesophageal junction, nasopharyngeal cancer, non-small cell lung cancer, esophageal cancer, duodenal cancer and recurrence or metastatic head and neck squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer and laryngeal cancer. It is administered by intravenous drip route. The drug candidate is an antibody-drug conjugate composed of a fully human anti-EGFR IgG1 monoclonal antibody conjugated to a microtubule disrupting agent monomethyl auristatin E (MMAE).
Shanghai Miracogen overview
Shanghai Miracogen., biotechnology company that offers development, clinical research and industrialization of new cancer targeted therapy drugs-the world’s cutting-edge technology Antibody Drug Conjugate (ADC) and innovative antibody anti-tumor drugs
For a complete picture of MRG-003’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
